查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
精神分裂症藥物市場與 COVID-19 影響分析，按治療類別、治療、配銷通路、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1339907

精神分裂症藥物市場與 COVID-19 影響分析，按治療類別、治療、配銷通路、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Schizophrenia Drugs Market with COVID-19 Impact Analysis, by Therapeutic Class, by Treatment, by Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年精神分裂症藥物市場規模為75.7921億美元，2023年至2030年年複合成長率為5.81%。

精神分裂症藥物市場-市場動態：

  • 精神分裂症及相關疾病的患病率不斷增加。
  • 精神分裂症和相關疾病發病率的增加，以及更容易患遲發性精神分裂症的人口老齡化，是整個預測期內推動市場擴張的主要驅動力。據世界衛生組織稱，到2022年，精神分裂症將影響全球2400萬人。此外，隨著人口普遍老齡化，這一數位預計將進一步上升。精神分裂症患病率的增加推動了對有效治療的需求，從而推動了精神分裂症藥物市場的發展。隨著越來越多的人被診斷出來，對控制症狀的藥物治療的需求也越來越大，這推動了該領域的研究、創新和市場開發。

精神分裂症藥物市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，全球精神分裂症藥物市場預計在預測期內（2023-2030）每年將以 5.81% 左右的年複合成長率成長
  • 由於精神分裂症及相關疾病的患病率不斷增加，精神分裂症藥物行業預計將以顯著的速度成長
  • 根據治療類別細分，預計第二代將在 2022 年顯示出最大的市場佔有率
  • 根據治療細分，注射劑是 2022 年的主導類型
  • 從分佈細分來看，醫院藥房是2022年的主導類型
  • 按地區分類，北美是 2022 年的主要收入來源

精神分裂症藥物市場-細分分析：

全球精神分裂症藥物市場根據治療類別、治療、配銷通路和地區進行細分。

市場根據治療類別分為幾類：第二代、第三代和其他。由於精神分裂症等精神健康疾病的發生頻率增加等因素，第二代抗精神病藥物預計將在預測期內成長，特別是在治療精神分裂症患者的妄想和幻覺等症狀方面特別有效。

市場根據治療分為兩類：口服和注射。注射劑市場佔據主導地位。注射型精神分裂症藥物，特別是長效注射劑 (LAI)，是最複雜的治療方法之一。長效注射劑通常有助於消除與口服精神分裂症治療相關的缺點。注射劑的一些優點包括提高對治療方案的依從性、減少復發以及避免患者出現不可逆的認知和神經損傷。

精神分裂症藥物市場-地理洞察：

從地域上看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區以及中東和非洲地區。這些區域根據開展業務的國家進一步分類。由於普通人群中精神分裂症和相關精神障礙的發病率不斷上升、醫療保健基礎設施健全、老年人口不斷增加、醫療保健支出高以及主要市場參與者的存在，預計北美將佔據重要的市場佔有率。根據國家精神疾病聯盟 (NAMI) 自 2022 年 6 月起的更新數據，精神分裂症每年影響美國約 150 萬成年人。因此，預計該地區對精神分裂症藥物的需求將會增加。將推動正在研究的北美市場的成長。

精神分裂症藥物市場-競爭格局：

公司通過多種管道銷售產品，包括企業網站、電子商務網站、零售商、分銷商和最終消費者。產品製造商在多個方面進行競爭，包括產品成本、性能、產品製造、技術、聲譽和可用性。企業用來擴大影響力和擴大市場佔有率的一些主要技術包括新產品發布、分銷網路開發、研發支出以及併購。例如，在 2022 年，為了研究、開發和銷售用於潛在治療神經精神疾病的新型多巴胺受體調節劑，艾伯維 (AbbVie) 和 Gedeon Richter 簽署了一項新的共同開發和許可協議。

最近的發展：

2023年5月，治療精神分裂症的全新藥物UZEDY獲得FDA批准。 UZEDY 是梯瓦製藥工業有限公司生產的一種藥物，採用共聚物技術在一到兩個月的時間內逐漸釋放活性成分利培酮。

該研究的主要特點：

  • 這項關於精神分裂症藥物市場的擬議研究提供了市場規模（百萬美元）、年複合成長率（CAGR%）和預測估計（2023-2030），以 2022 年為基準年
  • 該報告為客戶提供有關精神分裂症藥物市場的最新趨勢見解。
  • 該研究報告闡明了不同細分市場/國家的潛在成長機會，並解釋了精神分裂症藥物市場有吸引力的投資主張矩陣
  • 總體報告確定了新的投資機會、老牌參與者面臨的挑戰以及精神分裂症藥物市場維持的成長因素
  • COVID-19 對精神分裂症藥物市場規模、預測、年複合成長率和市場動態的影響將在研究範圍下詳細討論。還將詳細介紹新冠疫情后精神分裂症藥物市場的情況。
  • 為了讓本報告的用戶全面了解精神分裂症藥物市場，我們還包括了精神分裂症藥物市場的競爭格局和關鍵創新者分析。
  • 該研究包括成長前景映射分析，其中所有行業細分都根據其市場規模、成長率和吸引力進行基準測試。
  • 該報告提供了主要市場參與者的詳細公司概況，這將幫助用戶了解在精神分裂症藥物市場營運的參與者的財務資訊和戰略舉措。
  • 此外，報告還揭示了全球和區域市場主要參與者的重要收購和兼併、合作和合資、新產品推出、研發、區域擴張。
  • 全球精神分裂症藥物市場報告主要面向該行業的各個利益相關者，包括供應商、投資者、新進入者、分銷商和財務分析師

目錄

第一章：精神分裂症藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按治療類別分類的精神分裂症藥物市場片段
    • 精神分裂症藥物市場摘要（按治療）
    • 按配銷通路分類的精神分裂症藥物市場片段
    • 按國家/地區分類的精神分裂症藥物市場摘要
    • 按地區分類的精神分裂症藥物市場片段
  • 競爭洞察

第 3 章：精神分裂症藥物主要市場趨勢

  • 精神分裂症藥物市場促進因素
    • 市場促進因素的影響分析
  • 精神分裂症藥物市場限制
    • 市場限制影響分析
  • 精神分裂症藥物市場機會
  • 精神分裂症藥物市場未來趨勢

第 4 章：精神分裂症藥物行業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：精神分裂症藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的細分市場
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：精神分裂症藥物市場格局

  • 2022 年精神分裂症藥物市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：精神分裂症藥物市場 - 按治療類別

  • 概述
    • 按治療類別分類的細分市場佔有率分析
    • 第二代
    • 第三代
    • 其他

第 8 章：精神分裂症藥物市場 - 按治療分類

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 口服
    • 可注射

第 9 章：精神分裂症藥物市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥店
    • 網上藥店

第 10 章：精神分裂症藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美
    • 概述
    • 北美精神分裂症藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按治療類別）
    • 北美市場規模和預測（按不同處理方式）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲精神分裂症藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按治療類別）
    • 歐洲市場規模和預測（按處理方式）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區精神分裂症藥物主要製造商
    • 亞太地區市場規模和預測（按國家）
    • 亞太地區市場規模和預測（按治療類別）
    • 亞太地區市場規模和預測（按不同處理方式）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳大利亞
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲精神分裂症藥物主要製造商
    • 拉丁美洲市場規模和預測（按國家）
    • 拉丁美洲市場規模和預測（按治療類別）
    • 拉丁美洲市場規模和預測（按不同處理方式）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲精神分裂症藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按治療類別）
    • 中東和非洲市場規模及預測（按不同處理方式）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 火雞
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 精神分裂症藥物行業

  • 競爭儀表板
  • 公司簡介
    • Vanda Pharmaceuticals
    • Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
    • Sumitomo Dainippon Pharma
    • Recordati Rare Diseases
    • Pfizer
    • Otsuka Pharmaceutical
    • Novartis
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Intra-Cellular Therapies
    • H. Lundbeck A/S
    • Eli Lilly and Company
    • Bristol Myers Squibb
    • AstraZeneca
    • Allergan (now part of AbbVie)
    • Alkermes plc

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯繫我們
Product Code: ANV1631

REPORT HIGHLIGHT

Schizophrenia Drugs Market size was valued at USD 7,579.21 Million in 2022, expanding at a CAGR of 5.81% from 2023 to 2030.

Schizophrenia drugs are pharmacological chemicals that are used to treat the symptoms of schizophrenia, a complicated mental condition marked by disordered thoughts, feelings, and perceptions. These medications primarily target neurotransmitter imbalances in the brain, specifically dopamine and serotonin, in order to reduce hallucinations, delusions, disordered thinking, and social disengagement. Schizophrenia medications attempt to improve the quality of life for those suffering from the condition by reducing symptoms and increasing functional recovery, frequently as part of a complete treatment plan that includes counseling and psychological support.

Schizophrenia Drugs Market- Market Dynamics:

  • Increasing prevalence of schizophrenia and associated disorders.
  • The increased frequency of schizophrenia and related illnesses, along with an aging population that is more vulnerable to late-onset schizophrenia, is the primary driver driving market expansion throughout the projection period. According to the WHO, schizophrenia will affect 24 million people globally by 2022. Furthermore, with the aging of people in general, the figure is anticipated to rise further. The increased prevalence of schizophrenia is driving the need for effective treatment, moving the schizophrenia medications market forward. As more people are diagnosed, there is a larger demand for pharmacological treatments to control symptoms, which is fueling research, innovation, and market development in this sector.

Schizophrenia Drugs Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Schizophrenia Drugs market is estimated to grow annually at a CAGR of around 5.81% over the forecast period (2023-2030)
  • The Schizophrenia Drugs industry is projected to grow at a significant rate due to the increasing prevalence of schizophrenia and associated disorders
  • Based on therapeutic class segmentation, second generation was predicted to show maximum market share in the year 2022
  • Based on treatment segmentation, injectable was the leading type in 2022
  • Based on distribution segmentation, hospital pharmacies was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Schizophrenia Drugs Market- Segmentation Analysis:

The Global Schizophrenia Drugs Market is segmented on the basis of Therapeutic Class, Treatment, Distribution Channel, and Region.

The market is divided into categories based on therapeutic class: Second Generation, Third Generation, and Other. The Second-generation antipsychotics segment is expected to grow over the forecast period, owing to the factors such as the increased frequency of mental health illnesses such as schizophrenia, particularly effective in treating symptoms such as delusions and hallucinations in people with schizophrenia.

The market is divided into categories based on treatment: oral and injectable. The injectable segment dominates the market. Injectable-based schizophrenia medicines, particularly long acting injectables (LAIs), are among the most sophisticated kinds of therapy. Long-acting injectables frequently aid in the elimination of the drawbacks associated with oral schizophrenia therapy. Some of the advantages of the injectable include improved adherence to treatment regimens, reduced relapses, and the avoidance of irreversible cognitive and neurological impairment in patients.

Schizophrenia Drugs Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold a significant market share the market owing to the growing incidence of schizophrenia and associated mental disorders in the general population, the presence of robust healthcare infrastructure rising geriatric population, high spending on healthcare, and the presence of major market players. Schizophrenia affects about 1.5 million adults annually in the United States, in accordance to the National Alliance of Mental Illness (NAMI) update from June 2022. As a result, it is anticipated that there will be a demand for schizophrenia drugs in the area, which will drive growth in the North American market under study.

Schizophrenia Drugs Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, technology, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, in 2022, In order to conduct research, develop, and market novel dopamine receptor modulators for the potential treatment of neuropsychiatric illnesses, AbbVie and Gedeon Richter have engaged into a new co-development and license agreement.

Recent Developments:

In May 2023, UZEDY, a brand-new medication for the treatment of schizophrenia, received FDA approval. UZEDY is a medication produced by Teva Pharmaceutical Industries, Ltd. that gradually releases the active component, risperidone, over the course of one to two months using copolymer technology.

Key features of the study:

  • This proposed research study on Schizophrenia Drugs market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Schizophrenia Drugs market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Schizophrenia Drugs market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Schizophrenia Drugs market
  • Impact of COVID-19 on Schizophrenia Drugs market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Schizophrenia Drugs market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Schizophrenia Drugs market, we have also included competitive landscape and key innovator analysis for the Schizophrenia Drugs market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Schizophrenia Drugs market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Schizophrenia Drugs market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SCHIZOPHRENIA DRUGS MARKET KEY PLAYERS

  • Vanda Pharmaceuticals
  • Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
  • Sumitomo Dainippon Pharma
  • Recordati Rare Diseases
  • Pfizer
  • Otsuka Pharmaceutical
  • Novartis
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Intra-Cellular Therapies
  • H. Lundbeck A/S
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • AstraZeneca
  • Allergan (now part of AbbVie)
  • Alkermes plc

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS

  • Second Generation
  • Third Generation
  • Other

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT

  • Oral
  • Injectable

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Schizophrenia Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Schizophrenia Drugs Market Snippet by Therapeutic Class
    • 2.1.2. Schizophrenia Drugs Market Snippet by Treatment
    • 2.1.3. Schizophrenia Drugs Market Snippet by Distribution Channel
    • 2.1.4. Schizophrenia Drugs Market Snippet by Country
    • 2.1.5. Schizophrenia Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Schizophrenia Drugs Key Market Trends

  • 3.1. Schizophrenia Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Schizophrenia Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Schizophrenia Drugs Market Opportunities
  • 3.4. Schizophrenia Drugs Market Future Trends

4. Schizophrenia Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Schizophrenia Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Schizophrenia Drugs Market Landscape

  • 6.1. Schizophrenia Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Schizophrenia Drugs Market - By Therapeutic Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Class, 2022 & 2030 (%)
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Other

8. Schizophrenia Drugs Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable

9. Schizophrenia Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Schizophrenia Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Schizophrenia Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Schizophrenia Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Schizophrenia Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Schizophrenia Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Schizophrenia Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Schizophrenia Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Vanda Pharmaceuticals
    • 11.2.2. Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
    • 11.2.3. Sumitomo Dainippon Pharma
    • 11.2.4. Recordati Rare Diseases
    • 11.2.5. Pfizer
    • 11.2.6. Otsuka Pharmaceutical
    • 11.2.7. Novartis
    • 11.2.8. Johnson & Johnson (Janssen Pharmaceuticals)
    • 11.2.9. Intra-Cellular Therapies
    • 11.2.10. H. Lundbeck A/S
    • 11.2.11. Eli Lilly and Company
    • 11.2.12. Bristol Myers Squibb
    • 11.2.13. AstraZeneca
    • 11.2.14. Allergan (now part of AbbVie)
    • 11.2.15. Alkermes plc

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Schizophrenia Drugs Market: Therapeutic Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class
  • TABLE Global Schizophrenia Drugs Market, by Therapeutic Class 2018-2030 (USD Million)
  • TABLE Schizophrenia Drugs Market: Treatment Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Schizophrenia Drugs Market, by Treatment 2018-2030 (USD Million)
  • TABLE Schizophrenia Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Schizophrenia Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Schizophrenia Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Schizophrenia Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)